Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL negative |
| Therapy | Bemcentinib |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL negative | head and neck squamous cell carcinoma | decreased response | Bemcentinib | Preclinical | Actionable | In a preclinical study, Bemcentinib (BGB-324) did not inhibit proliferation or invasion of AXL-negative head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). | 25767293 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25767293) | AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. | Full reference... |